Vir Biotechnology entered into an underwriting agreement to sell 15,000,000 shares of common stock at a public offering price of $10.00 per share. The company expects to receive approximately $140.4 million in net proceeds, or $161.5 million if the underwriters exercise their 30-day option to purchase an additional 2,250,000 shares.
Vir Biotechnology announced positive topline results from its pivotal Phase 3 ECLIPSE 1 trial evaluating a combination of elebsiran and tobevibart for chronic hepatitis delta. The trial met its primary endpoint with a 44% response rate (undetectable virus plus ALT normalization) at Week 48 compared to 0% in the delayed treatment group, demonstrating a favorable safety profile with no treatment discontinuations.
Vir Biotechnology reported a significant increase in total revenues to $238.7 million for the nine months ended September 30, 2026, primarily driven by license and collaboration revenue. Despite this, the company recorded a net loss of $141.9 million for the same period, though this was a substantial improvement from the $395.1 million net loss in the prior year due to higher revenues and reduced research and development expenses.
Vir Biotechnology reported third-quarter 2026 financial results, ending the period with $901 million in cash and investments. The company highlighted upcoming Phase 3 data for its hepatitis delta program and the receipt of FDA Fast Track designation for its oncology candidate VIR-5500.
“We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology. We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the significant unmet need for patients with a therapy that can drive hepatitis delta virus to undetectable. In oncology, VIR-5500 achieved proof of concept and received FDA Fast Track designation, supporting our plans with Astellas to advance the program into pivotal trials next year. With momentum across both areas, we believe Vir Bio is well positioned to deliver meaningful value for patients and stakeholders.”
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
Vir Biotechnology EVP, General Counsel, Corp Sec Verneuil Vanina de Sells $41.9K of Stock
Verneuil Vanina de, EVP, General Counsel, Corp Sec, sold 3,750 shares of Vir Biotechnology, Inc. at $11.10 to $11.33 a share (average $11.18) in 2 transactions, worth $41.9K in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 110,193 (-2.1%).
Vir Biotechnology appointed Suzanne Topalian, M.D., to its Board of Directors and the Science and Technology Committee, effective October 27, 2026. As a non-employee director, she will receive standard cash and equity compensation, including stock options and restricted stock units under the company's 2019 Equity Incentive Plan. The board size was increased from eight to nine members to accommodate the appointment.
Vir Biotechnology Research Collaboration with Gilead Sciences, Inc. Worth $1.88B
Vir Biotechnology and Gilead Sciences have entered into a global strategic collaboration to discover and engineer three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates for solid tumors. Vir receives $90 million in upfront consideration (including a $25 million equity investment at a 30% premium) and is eligible for up to $1.785 billion in total potential milestones plus royalties.
Vir Biotechnology announced that the FDA has granted Fast Track designation to VIR-5500, a PSMA-targeted T-cell engager being co-developed with Astellas Pharma for the treatment of metastatic castration-resistant prostate cancer. The designation is intended to expedite the development and review of the drug, which is currently in Phase 1 trials with Phase 3 development anticipated to begin in 2027.
Vir Biotechnology appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026. His compensation package includes an annual base salary of $520,000, a $150,000 sign-on bonus, and equity awards consisting of 150,000 stock options and 75,000 restricted stock units.